AstraZeneca ends contract sales agreement with PDI

Share this article:
Contract sales-force provider PDI said that its fee-for-service agreements with AstraZeneca would be terminated effective April 30. The termination affects approximately 800 field representatives. The revenue impact is projected to be approximately $65 million to $70 million in 2006, PDI said. “We have worked with AstraZeneca for over 12 years and look forward to creating future business opportunities with them. We are vigorously exploring potential opportunities to redeploy these high performing sales teams,” said PDI’s president Steven Budd in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.